Patents by Inventor Michael P. Graziano
Michael P. Graziano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120079616Abstract: The present invention provides human, rat and mouse NPC1L1 polypeptides and polynucleotides encoding the polypeptides. Also provided are methods for detecting agonists and antagonists of NPC1L1. Inhibitors of NPC1L1 can be used for inhibiting intestinal cholesterol absorption in a subject.Type: ApplicationFiled: October 12, 2011Publication date: March 29, 2012Applicant: Schering CorporationInventors: Scott W. Altmann, Nicholas J. Murgolo, Luquan Wang, Michael P. Graziano
-
Patent number: 7723020Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.Type: GrantFiled: October 25, 2006Date of Patent: May 25, 2010Assignee: Schering CorporationInventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Jr., Michael P. Graziano, Maureen Laverty, Xiaorui Yao
-
Patent number: 7442712Abstract: A compound represented by the structural formula and pharmaceutically acceptable salts and solvents thereof is disclosed, wherein: the single-dashed line between the ring carbons to which R10 and R34 are attached represents either a single bond or a double bond; the double-dashed line between X and the carbon to which Y is attached represents either a single bond or an absent bond; X is —O— or —NR6— when the double-dashed line represents a single bond; X is H, —OH or —NHR20 when the double-dashed line represents an absent bond; and other parameters are as defined herein. Also disclosed are pharmaceutical compositions and combinations containing said compounds and their uses as thrombin receptor antagonists and binders to cannabinoid receptors.Type: GrantFiled: May 25, 2005Date of Patent: October 28, 2008Assignee: Schering CorporationInventors: Mariappan V. Chelliah, Samuel Chackalamannil, Yan Xia, Martin C. Clasby, William J. Greenlee, Yuguang Wang, Enrico P. Veltri, Wenxue Wu, Michael P. Graziano, Teddy Kosoglou, Madhu Chintala
-
Patent number: 7144696Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.Type: GrantFiled: May 6, 2005Date of Patent: December 5, 2006Assignee: Schering CorporationInventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Jr., Michael P. Graziano, Maureen Laverty, Xiaorui Yao
-
Patent number: 7135556Abstract: We claim an isolated polypeptide having ability of binding with cholesterol. Said polypeptide is useful for investigating regulation of intestinal cholesterol absorption and cholesterol levels. Also, we claim a composition comprising said polypeptide bound to cholesterol or ezetimibe and a fusion protein comprising the polypeptide thereof.Type: GrantFiled: December 16, 2003Date of Patent: November 14, 2006Assignee: Schering CorporationInventors: Scott W. Altmann, Nicholas J. Murgolo, Luquan Wang, Michael P. Graziano
-
Patent number: 6933107Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.Type: GrantFiled: May 15, 2003Date of Patent: August 23, 2005Assignee: Schering CorporationInventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Jr., Michael P. Graziano, Maureen Laverty, Xiaorui Yao
-
Publication number: 20040192753Abstract: A method of treating a therapeutic condition comprising administering to a mammal in need of such treatment an effective amount of at least one compound of the formulas: 1Type: ApplicationFiled: November 10, 2003Publication date: September 30, 2004Inventors: Samuel Chackalamannil, Yan Xia, Enrico P. Veltri, Mariappan V. Chelliah, Wenxue Wu, Michael P. Graziano, Teddy Kosoglou, Madhu Chintala
-
Publication number: 20040176418Abstract: A crystalline polymorph of a bislulfate salt of a thrombin receptor antagonist compound, which exhibits a powder x-ray diffraction profile substantially the same as that shown in FIG. 1, or which exhibits a differential scanning calorimtery profile substantially the same as that shown in FIG.Type: ApplicationFiled: January 9, 2004Publication date: September 9, 2004Applicant: Schering CorporationInventors: Tiruvettipuram K. Thiruvengadam, Wenxue Wu, Tao Wang, John S. Chiu, Susan Bogdanowich-Knipp, Anastasia Pavlovsky, William J. Greenlee, Michael P. Graziano, Teddy Kosoglou, Madhu Chintala, Samuel Chackalamannil
-
Publication number: 20040161838Abstract: The present invention provides human, rat and mouse NPC1L1 polypeptides and polynucleotides encoding the polypeptides. Also provided are methods for detecting agonists and antagonists of NPC1L1. Inhibitors of NPC1L1 can be used for inhibiting intestinal cholesterol absorption in a subject.Type: ApplicationFiled: December 16, 2003Publication date: August 19, 2004Applicant: Schering CorporationInventors: Scott W. Altmann, Nicholas J. Murgolo, Luquan Wang, Michael P. Graziano
-
Publication number: 20040137467Abstract: The present invention provides rat and mouse NPC1L1 polypeptides and polynucleotides encoding the polypeptides. Also provided are methods for detecting agonists and antagonists of NPC1L1. Inhibitors of NPC1L1 can be used for inhibiting intestinal cholesterol absorption in a subject.Type: ApplicationFiled: August 22, 2003Publication date: July 15, 2004Applicant: Schering CorporationInventors: Scott W. Altmann, Nicholas J. Murgolo, Luquan Wang, Michael P. Graziano
-
Publication number: 20040132058Abstract: The present invention provides rat and mouse NPC1L1 polypeptides and polynucleotides encoding the polypeptides. Also provided are methods for detecting agonists and antagonists of NPC1L1. Inhibitors of NPC1L1 can be used for inhibiting intestinal cholesterol absorption in a subject.Type: ApplicationFiled: September 16, 2003Publication date: July 8, 2004Applicant: Schering CorporationInventors: Scott W. Altmann, Nicholas J. Murgolo, Luquan Wang, Michael P. Graziano
-
Publication number: 20040097482Abstract: The present invention provides compositions, therapeutic combinations and methods including: (a) at least one HM74 or HM74A agonist and (b) at least one substituted azetidinone or substituted &bgr;-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.Type: ApplicationFiled: August 13, 2003Publication date: May 20, 2004Applicant: Schering CorporationInventors: Harry R. Davis, Teddy Kosoglou, Michael P. Graziano, Joseph A. Hedrick
-
Publication number: 20040093629Abstract: The present invention provides rat and mouse NPC1L1 polypeptides and polynucleotides encoding the polypeptides. Also provided are methods for detecting agonists and antagonists of NPC1L1. Inhibitors of NPC1L1 can be used for inhibiting intestinal cholesterol absorption in a subject.Type: ApplicationFiled: July 17, 2003Publication date: May 13, 2004Applicant: Schering CorporationInventors: Scott W. Altmann, Nicholas J. Murgolo, Lu Quan Wang, Michael P. Graziano
-
Publication number: 20030215869Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.Type: ApplicationFiled: May 15, 2003Publication date: November 20, 2003Inventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Michael P. Graziano, Maureen Laverty, Xiaorui Yao
-
Patent number: 6632933Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.Type: GrantFiled: July 30, 2001Date of Patent: October 14, 2003Assignee: Schering CorporationInventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Jr., Michael P. Graziano, Maureen Laverty, Xiaorui Yao
-
Patent number: 6593078Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.Type: GrantFiled: April 12, 2000Date of Patent: July 15, 2003Assignee: Schering CorporationInventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Jr., Michael P. Graziano, Maureen Laverty, Xiaorui Yao
-
Publication number: 20020009714Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.Type: ApplicationFiled: July 30, 2001Publication date: January 24, 2002Inventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Michael P. Graziano, Maureen Laverty, Xiaorui Yao
-
Patent number: 5889167Abstract: A synthetic human glucagon (hGlu) binding protein designated hGlu.DELTA.252-259 binding protein is cloned, expressed and used in an in vitro assay to screen for compounds that bind to the synthetic binding protein, including compounds that specifically stimulate or inhibit the binding of glucagon to the synthetic receptor. The invention includes the assay, the synthetic binding protein used in the assay, DNA encoding the synthetic binding protein, cells expressing the synthetic binding protein, and compounds identified through the use of the synthetic binding protein.Type: GrantFiled: May 21, 1997Date of Patent: March 30, 1999Assignee: Merck & Co., Inc.Inventors: Margaret A. Cascieri, Gary A. Chicchi, Michael P. Graziano, Patricia J. Hey